RxDoctor Payments Data

Asoka Ratnayake, MD

Family Medicine · Indianapolis, INNPI 1942405865

Payments from drug & device makers

$199in general payments, 2019–2025

Across 12 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$60
  • Pfizer$46
  • Boston Scientific$20
  • Astellas Pharma US Inc$20
  • RGH Enterprises LLC$16
  • Lundbeck LLC$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott3$60
Pfizer3$46
Boston Scientific1$20
Astellas Pharma US Inc1$20
RGH Enterprises LLC1$16
Lundbeck LLC1$14
Novo Nordisk1$12
GSK1$11

How this compares

$199 in reported general payments places this provider in the 30th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$109,297
Medicare patients
285
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$166,652
JardianceEmpagliflozin127$152,072
TrulicityDulaglutide39$70,561
FarxigaDapagliflozin Propanediol41$49,991
EliquisApixaban41$39,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$30,054
AbrysvoRsv Vacc, Pref A And Pref B/Pf88$27,852
JanuviaSitagliptin Phosphate16$19,595
XareltoRivaroxaban13$18,836
TrintellixVortioxetine Hydrobromide17$12,047
Arnuity ElliptaFluticasone Furoate28$9,033
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,357
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,301
TradjentaLinagliptin11$6,738
Atorvastatin Calcium716$6,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$166,652103 claims
PfizerEliquis, Abrysvo$46$66,987129 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Shingrix, Anoro Ellipta, Breo Ellipta$11$60,495115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →